Dr Justin Loke BM BCh PhD MRCP FRCPath

Dr Justin Loke

Institute of Cancer and Genomic Sciences
AACR- CRUK Transatlantic Fellow

Contact details

Centre for Clinical Haematology
Queen Elizabeth Hospital
Mindelsohn Way
B15 2GW

Dr Justin Loke trained at University of Cambridge and Oxford Medical School and then completed postgraduate haematology training in Birmingham. His specialist interest is in Acute Myeloid Leukaemia (AML) and he completed a PhD at the University of Birmingham under the supervision of Professor Constanze Bonifer in the epigenetic deregulation of AML, for which he was awarded a number of prizes from the Royal Society of Medicine and the Royal College of Pathologists.

Dr Loke subsequently completed a post-CCT fellowship with CRUK Clinical Trials Unit, Birmingham, and was a Consultant Haematologist at the Queen Elizabeth Hospital, Birmingham where he was involved in the development of supportive care studies in AML (PACE) and in the running of IMPACT transplant studies. 

He is currently an AACR-CRUK Transatlantic Fellow based in the Dana Farber Cancer Institute, Boston, USA with Professor Ben Ebert.


  • Fellow of the Royal College of Pathologists 2018
  • PhD, University of Birmingham 2017
  • Member of the Royal College of Physicians 2011
  • BM BCh, University of Oxford 2008
  • Master of Arts, University of Cambridge 2005


  • Teaching programme for the West Midlands Haematology Registrars
  • Associate of Higher Education Academy

Other activities

  • NCRI AML Working Party Subgroup
  • NCRI AML Supportive Care Secretary
  • EBMT Acute Leukaemia Working Party
  • Certificate of Completion of Training- Haematology 2019


Recent publications


Loke, J, Labopin, M, Craddock, C, Socié, G, Gedde‐Dahl, T, Blaise, D, Forcade, E, Salmenniemi, U, Huynh, A, Versluis, J, Yakoub‐Agha, I, Labussière‐Wallet, H, Maertens, J, Passweg, J, Bulabois, CE, Gabellier, L, Mielke, S, Castilla‐Llorente, C, Deconinck, E, Brissot, E, Nagler, A, Ciceri, F & Mohty, M 2024, 'Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party European Society for Blood and Marrow Transplantation study', Cancer. https://doi.org/10.1002/cncr.35308

Loke, J, Upasani, V, Gaskell, C, Fox, S, Fletcher, R, Thomas, C, Hopkins, L, Kumari, A, Tang, T, Yafai, E, Boucher, R, Homer, V, Toth, A, Chan, YLT, Randall, K, Rider, T, O'nions, J, Drew, V, Pillai, A, Dungarwalla, M, Murray, D, Khan, A, Wandroo, F, Moore, S, Krishnamurthy, P, Huang, YJ, Knapper, S, Byrne, J, Zhao, R, Craddock, C, Parry, H, Moss, P, Stanworth, SJ & Lowe, DM 2023, 'Defective T‐cell response to COVID‐19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes', British Journal of Haematology, vol. 202, no. 3, pp. 498-503. https://doi.org/10.1111/bjh.18894

Loke, J, McCarthy, N, Jackson, A, Siddique, S, Hodgkinson, A, Mason, J, Crawley, C, Gilleece, M, Peniket, A, Protheroe, R, Salim, R, Tholouli, E, Wilson, K, Andrew, G, Dillon, R, Khan, N, Potter, V, Krishnamurthy, P, Craddock, C & Freeman, S 2023, 'Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS', Blood Advances, vol. 7, no. 14, pp. 3666-3676. https://doi.org/10.1182/bloodadvances.2022009493

Loke, J, Labopin, M, Craddock, C, Cornelissen, JJ, Labussière-Wallet, H, Wagner-Drouet, EM, Van Gorkom, G, Schaap, NPM, Kröger, NM, Veelken, JH, Rovira, M, Menard, AL, Bug, G, Bazarbachi, A, Giebel, S, Brissot, E, Nagler, A, Esteve, J & Mohty, M 2022, 'Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia', Cancer, vol. 128, no. 15, pp. 2922-2931. https://doi.org/10.1002/cncr.34268

Loke, J, Metzner, M, Boucher, R, Jackson, A, Hopkins, L, Pavlu, J, Tholouli, E, Drummond, M, Peniket, A, Bishop, R, Fox, S, Vyas, P & Craddock, C 2021, 'Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy', British Journal of Haematology. https://doi.org/10.1111/bjh.17823

Craddock, C, Jackson, A, Loke, J, Siddique, S, Hodgkinson, A, Mason, J, Andrew, G, Nagra, S, Malladi, R, Peniket, A, Gilleece, M, Salim, R, Tholouli, E, Potter, V, Crawley, C, Wheatley, K, Protheroe, R, Vyas, P, Hunter, A, Parker, A, Wilson, K, Pavlu, J, Byrne, J, Dillon, R, Khan, N, Mccarthy, N & Freeman, SD 2020, 'Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.02308

Assi, SA, Imperato, MR, Coleman, DJL, Pickin, A, Potluri, S, Ptasinska, A, Chin, PS, Blair, H, Cauchy, P, James, SR, Zacarias-cabeza, J, Gilding, LN, Beggs, A, Clokie, S, Loke, JC, Jenkin, P, Uddin, A, Delwel, R, Richards, SJ, Raghavan, M, Griffiths, MJ, Heidenreich, O, Cockerill, PN & Bonifer, C 2019, 'Subtype-specific regulatory network rewiring in acute myeloid leukemia', Nature Genetics, vol. 51, no. 1, pp. 151-162. https://doi.org/10.1038/s41588-018-0270-1

Loke, J, Chin, PS, Keane, P, Pickin, A, Assi, S, Ptasinska, A, Imperato, M, Cockerill, P & Bonifer, C 2018, 'C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia', Blood Advances, vol. 2, no. 3, pp. 271-284. https://doi.org/10.1182/bloodadvances.2017012781, https://doi.org/10.1182/bloodadvances.2017012781

Malaker, SA, Penny, SA, Steadman, LG, Myers, PT, Loke, JC, Raghavan, M, Bai, DL, Shabanowitz, J, Hunt, DF & Cobbold, M 2017, 'Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia', Cancer immunology research, vol. 5, no. 5, pp. 376-384. https://doi.org/10.1158/2326-6066.CIR-16-0280

Loke, J, Assi, SA, Imperato, MR, Ptasinska, A, Cauchy, P, Grabovska, Y, Soria, NM, Raghavan, M, Delwel, HR, Cockerill, PN, Heidenreich, O & Bonifer, C 2017, 'RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML', Cell Reports, vol. 19, no. 8, pp. 1654-1668. https://doi.org/10.1016/j.celrep.2017.05.005

Loke, J, Akiki, S, Borrow, J, Ewing, J, Bokhari, S, Chandra, D, Arrazi, J, Hazlewood, P, Arthur, K, Walsh, J, Membwange, Y, Wandroo, F, Watts, A, Borg, A, Brock, K, Ferguson, P, Craddock, C, Griffiths, M & Raghavan, M 2015, 'Acquired Isodisomy on Chromosome 13 at diagnosis results in impaired overall survival in Patients with FLT3-ITD mutant Acute Myeloid Leukaemia', Leukemia, vol. 29, no. 12, pp. 2404-2407. https://doi.org/10.1038/leu.2015.148

Review article

Kinsella, FAM, Maroto, MAL, Loke, J & Craddock, C 2024, 'Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia', British Journal of Haematology. https://doi.org/10.1111/bjh.19463

Loke, J, Buka, R & Craddock, C 2021, 'Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?', Frontiers in immunology, vol. 12, 659595. https://doi.org/10.3389/fimmu.2021.659595

Loke, J, Vyas, H & Craddock, C 2021, 'Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia', Frontiers in Oncology, vol. 11, 666091. https://doi.org/10.3389/fonc.2021.666091

Loke, J, Malladi, R, Moss, P & Craddock, C 2019, 'The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience', British Journal of Haematology, vol. 188, no. 1, pp. 129-146. https://doi.org/10.1111/bjh.16355

View all publications in research portal